Originally published on LinkedIn. Follow me, Harold Hare, for insights on disruptive industries shaping startups and enterprise.
Grow Therapy has raised a $150 million Series D led by TCV and Goldman Sachs Alternatives, bringing its valuation to $3 billion. The round included new investors Menlo Ventures and BCI alongside existing backers such as Sequoia, SignalFire, and Transformation Capital. Chief Executive Officer Jake Cooper said the company now generates more than $1 billion in annual revenue and reached profitability in 2023. Founded in 2020, the platform combines revenue scale and profitability rarely seen at this stage of growth.
From Access Marketplace to Integrated Platform
Grow Therapy connects patients with therapists and psychiatrists who accept insurance, while handling administrative processes such as credentialing and billing. The company says 220 million people can access its services through their existing insurance coverage. Over the past five years, more than two million people nationwide have used the platform. In 2025 alone, it facilitated seven million visits, bringing the lifetime total to 10 million therapy and medication management appointments. The provider network has grown to 26,000 clinicians delivering in-person and virtual care. Insurance partnerships have expanded from 75 to more than 125 payers, including Medicare and Medicaid. On average, clients pay $21 per visit, and one in three pay nothing out of pocket. Scale here is measured in insured access, visit volume, and provider participation rather than consumer downloads alone.
Outcomes as Operating Infrastructure
In April 2024, Grow announced an $88 million Series C tied to the launch of measurement-informed care systems. Those systems collect and analyze clinical assessments, integrate outcome tracking into treatment plans, and embed prompts into clinician workflows. The company detailed proprietary telehealth infrastructure integrated with electronic health records and enhancements to patient-provider matching algorithms. At the time, Grow reported more than three million patient encounters, a four-day average time-to-care, and strong satisfaction metrics.
Outcome measurement now sits at the center of its operating model. The company reports that 80% of clients see measurable symptom improvement within 30 days. It has introduced clinically guided AI-assisted notes for providers, with internal data indicating documentation time dropped nearly 70% while maintaining accuracy. A patient-facing app offers AI-supported journaling between sessions, with optional sharing of insights with clinicians before appointments. Earlier this year, the company acquired AI scribe Tenor to further reduce documentation burdens. These tools are embedded within clinical workflows, focusing on documentation efficiency, structured reflection, and more productive session time.
Entering Employers and Health Systems
The next growth phase extends beyond direct patient acquisition. Grow is expanding into employer-sponsored mental health benefits and deeper partnerships with health systems. Employer assistance programs and insurance coverage often operate separately, requiring employees to switch providers or pay out of pocket after limited sessions. Grow is positioning itself as a connected pathway that allows employees to transition seamlessly into insurance-covered care while retaining the same clinician.
The company is also extending coordination with health systems, including Circle Medical, to improve referrals and reduce friction between primary care and mental health treatment. For employers, the model emphasizes paying only for care delivered rather than flat fees. For health systems, the focus centers on coordinated referrals and continuity. Each expansion adds a new buyer and stakeholder layer to the platform’s operating model.
Competition at Enterprise Scale
Bloomberg identified competitors such as Headway and Alma, with Alma set to be acquired by employer-focused mental health company Spring Health. Capital continues to concentrate around platforms that aggregate providers, integrate with insurance, and demonstrate measurable outcomes. Differentiation now centers on operational reliability, breadth of integration, and measurable performance.
As Grow expands across payers, employers, and health systems, enterprise expectations rise. Each contract brings reporting requirements, quality benchmarks, and service-level standards that shape how the platform operates at scale.
Culture as Execution Strategy
Fortune reported that the company employs 458 people and offers a $1,400 annual wellness stipend for personal development, therapy, or related expenses. Employees also have access to weekly “Mental Health Mornings” or “Afternoons,” allowing schedule flexibility. Leadership has described alignment between mission and employee experience as central to the company’s culture.
For a platform built around mental health outcomes, workforce sustainability influences product development, provider recruitment, and enterprise execution. Internal policies become part of operational capacity when scaling to thousands of clinicians and millions of visits.
Private Capital Over Public Markets
Despite its revenue scale and profitability, an initial public offering is not an immediate priority. Cooper has stated that the company sees continued support in private markets and believes it can build more effectively without going public. Late-stage health technology companies with established revenue continue to access significant private capital without entering public markets.
The Next Phase
The operational test now spans multiple stakeholders. Insurers evaluate outcome data and cost alignment. Employers examine utilization, continuity, and budget predictability. Health systems expect coordinated referrals and smooth transitions. Providers look for efficient tools and manageable workloads. Patients expect accessible, affordable care through plans they already use.
The $150 million Series D gives the company room to expand into employer contracts, deepen primary care integration, and continue investing in its technology stack. That capital sits on top of more than $1 billion in annual revenue and profitability reached in 2023. At the same time, reported outcome improvements, reduced documentation time, and expanded insurance partnerships create the operational base needed to support that next phase of growth.
At this scale, execution defines performance. Platforms that span payers, employers, health systems, and independent clinicians require disciplined coordination at scale. Grow Therapy’s trajectory shows how integrated infrastructure, insurance alignment, outcome measurement, and late-stage capital operate together at enterprise scale.
